Brexpiprazole pharmacokinetics in CYP2D6 poor metabolizers: Using physiologically-based pharmacokinetic modeling to optimize time-to-effective concentrations (JCP-21-Apr-211-R2).
Sign Up to like & getrecommendations! Published in 2021 at "Journal of clinical pharmacology"
DOI: 10.1002/jcph.1946
Abstract: Brexpiprazole is an oral antipsychotic agent indicated for use in patients with schizophrenia, or as adjunctive treatment for major depressive disorder (MDD). As CYP2D6 contributes significantly to brexpiprazole metabolism, there is a label-recommended 50% reduction… read more here.
Keywords: based pharmacokinetic; physiologically based; time effective; effective concentrations ... See more keywords
Effect of CYP2D6 Poor Metabolizer Phenotype on Stereoselective Nebivolol Pharmacokinetics.
Sign Up to like & getrecommendations! Published in 2018 at "Drug metabolism letters"
DOI: 10.2174/1872312812666180420104945
Abstract: BACKGROUND Nebivolol is a drug available as a racemate of d-nebivolol (SRRR) and lnebivolol (RSSS). In human liver microsomes, CYP2D6 mainly catalyses the metabolism of lnebivolol, while CYP2C19 catalyses the metabolism of d-nebivolol. Nebivolol stereoselective… read more here.
Keywords: phenotype; nebivolol pharmacokinetics; effect cyp2d6; cyp2d6 ... See more keywords